Prana Announces That New York Academy of Sciences eBriefing Is Available Online

Prana Announces That New York Academy of Sciences eBriefing Is Available Online 
'Targeting Metals in Alzheimer's and Other Neurodegenerative
Diseases' Symposium 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 01/29/13 --  Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that the New
York Academy of Sciences eBriefing which provides information and
video footage of the symposium which took place on November 29th
titled "Targeting Metals in Alzheimer's and Other Neurodegenerative
Diseases" is now available for viewing by the public by going to:
www.nyas.org/MetalsandAD-eB. The eBriefing features multimedia
presentations of speakers' slides and audio, written meeting summary,
and links to related resources. 
Dr. Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of
Neurology at Harvard University and Prana's Chief Scientific Advisor,
and Dr. Robert Cherny, Prana's Head of Research, are featured in the
eBriefing. The presentations explore in depth the causative events
leading to the neuropathology that drives Alzheimer's disease,
Parkinson's disease and Huntington disease. This symposium examined
how these findings led to the discovery of small molecules designed
to restore the balance of transition metals in the brain that are
critical for neuronal function, reduce the accumulation of aggregated
target proteins, and could have a disease-modifying effect. A review
of Prana's PBT2 clinical history is also presented.  
According to Geoffrey Kempler, Chairman of Prana, "We are pleased to
make available to the public the eBriefing of the Symposium which
recently took place at the New York Academy of Sciences. We believe
it provides a clear synopsis and overview of the potential of Prana's
PBT in treating Alzheimer's and Huntington diseases." Recently, Prana
announced that it has completed enrollment in its ongoing 6 month
Phase 2 trial in Huntington patients and 12-month Phase 2 trial in
Alzheimer's disease patients.  
Dr. Tanzi said, "As more and more scientists in the Alzheimer's field
generate data on the role of metals in neurodegenerative disease, we
are becoming increasingly optimistic about the prospects for Prana's
trials. Elucidation of new Alzheimer's genes continues to support the
excessive accumulation of the amyloid beta protein in th
e brain as
the triggering event for this devastating disease. Prana's
therapeutic strategy for treating neurodegenerative disease involves
a very different mechanism of action than that of other
anti-beta-amyloid drugs, which have largely failed. In light of these
failures, many in the field have deemphasized efforts to treat
existing Alzheimer's patients and are focusing on prevention. I
believe that PBT2 has a very good chance of success for not only
helping to prevent Alzheimer's, but also for providing real benefit
to the millions of existing patients in need of effective
treatments." 
About Prana Biotechnology Limited
 Prana Biotechnology was
established to commercialize research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and
listed on the Australian Securities Exchange in March 2000 and listed
on NASDAQ in September 2002. Researchers at prominent international
institutions including The University of Melbourne, The Mental Health
Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the
discovery of Prana's technology.  
For further information please visit the Company's web site at
www.pranabio.com. 
About the New York Academy of Sciences
 The New York Academy of
Sciences is an independent, not-for-profit organization committed to
advancing science, technology, and society worldwide since 1817. With
25,000 members in 140 countries, the Academy is creating a global
community of science for the benefit of humanity. The Academy's core
mission is to advance scientific knowledge, positively impact the
major global challenges of society with science-based solutions, and
increase the number of scientifically informed individuals in society
at large. Visit www.nyas.org for more information on the Academy.  
Forward-Looking Statements 
 This press release contains
"forward-looking statements" within the meaning of section 27A of the
Securities Act of 1933 and section 21E of the Securities Exchange Act
of 1934. The Company has tried to identify such forward-looking
statements by use of such words as "expects," "intends," "hopes,"
"anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not
the exclusive means of identifying such statements. Such statements
include, but are not limited to any statements relating to the
Company's drug development program, including, but not limited to the
initiation, progress and outcomes of clinical trials of the Company's
drug development program, including, but not limited to, PBT2, and
any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those
risks and uncertainties relating to the difficulties or delays in
financing, development, testing, regulatory approval, production and
marketing of the Company's drug components, including, but not
limited to, PBT2, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds,
including, but not limited to, PBT2, that could slow or prevent
products coming to market, the uncertainty of patent protection for
the Company's intellectual property or trade secrets, including, but
not limited to, the intellectual property relating to PBT2, and other
risks detailed from time to time in the filings the Company makes
with Securities and Exchange Commission including its annual reports
on Form 20-F and its reports on Form 6-K. Such statements are based
on management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements
as a prediction of actual future results. 
Contacts: 
Australia
Prana Biotechnology
+61 3 9349 4906 
US
Leslie Wolf-Creutzfeldt
T: 646-284-9472
E: leslie.wolf-creutzfeldt@grayling.com